% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

  • atermofcondition atermofcondition Apr 14, 2013 11:15 AM Flag

    New Investor, looking for realistic overview

    Can someone that follow CURIS please provide me with a realistic overview of the company, it's products, and fiscal forecast?


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • CUDC 907 HDAC+PI3k in my opinion could be a gem. Currently in Ph1 trial... Compare against INFI drug that made it go from 6 to 50... IAP inhibitor to start ph2 testing mid year molecule was created by genentech and licensed to Curis... abstract on ph1 to be released at asco. hsp90 outlicensed to debiopharm who is taking forever to enroll patients.... Erivedge slow start to sales... Waiting for operable bcc data in the near future to expand use....

    • They have one approved product that works well. Sales are increasing Q by Q. Their royalty with Roche is very low and the main disadvantage. several international trials and submissions can result in approvals this year. This coming week, we will continue slow buying and larger volumes. I am not sure when they will announce Q1 but Roche already was positive that I posted earlier.

2.77+0.02(+0.73%)Oct 25 4:00 PMEDT